To Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer
A Clinical Trial to Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer
Yong Wha Moon
6 participants
Apr 1, 2025
INTERVENTIONAL
Conditions
Summary
The objective of this clinical trial is to evaluate the safety of autologous tumor-infiltrating lymphocytes and to investigate their efficacy in recurrent ovarian cancer. Participants undergo the following process: There must be a cancerous lesion available for biopsy or surgery, and enhanced tumor-infiltrating lymphocytes are cultured from ovarian cancer tissue collected from the subject. These are processed into human cells for administration and injected into the subject.
Eligibility
Inclusion Criteria2
- Recurrent ovarian cancer
- There is a cancerous lesion that can be removed by biopsy or surgery.
Exclusion Criteria2
- Patient with immunodeficiency or autoimmune diseases that may be exacerbated by immunotherapy
- Patient deemed unsuitable by the principal investigator
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Autologous tumor-infiltrating lymphocytes are cultured from tumor cells collected from the subject and administered as a single intravenous injection to the subject.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07651124